亚胺培南

yà àn péi nán
  • Imipenem
亚胺培南亚胺培南
  1. 亚胺培南在痂下组织液中在用药后1h即可以检测到,有效浓度可维持6~8h。

    The effective concentrations of Imipenem could maintain 6 ~ 8h .

  2. 对亚胺培南、美罗培南、多黏菌素B、多黏菌素E的耐药性较低,分别为22.4%、22.4%、0%、10.2%。

    The resistant rates of imipenem , meropenem , polymycin B and polymycin E were 22.4 % , 22.4 % , 0 % and 10.2 % separately .

  3. 亚胺培南、多黏菌素E是治疗鲍氏不动杆菌感染最有效的抗生素。

    Imipenem and polymyxin E are the most effective antibiotics for Acinetobacter baumannii .

  4. 亚胺培南诱导生物被膜肺炎克雷伯菌(C组)超广谱β-内酰胺酶的检出率为65.0%(26/40)。

    The isolation rate of ESBLs producting strains in klebsiella biofilm being induced by imipenem were 65.0 % ( 26 / 40 ) .

  5. 亚胺培南和头孢他啶治疗铜绿假单胞菌败血症诱导TNF的实验研究

    Experimental study on TNF induced by imipenem and ceftazidime in treatment of Pseudomonas aeruginosa septicemia

  6. 运用PCRmapping、DNA测序技术和生物信息学手段,对一株临床分离耐亚胺培南铜绿假单胞菌进行整合子结构分析。

    With PCR-mapping , DNA sequencing and bioinformatics approach , structure of an integron in a clinical isolate of Pseudomonas aeruginosa resisting to imipenem was studied .

  7. 产ESBLs菌对亚胺培南的的敏感率为100%。

    The susceptibility rate of all ESBLs-producing strains to imipenem was 100 % .

  8. 对于耐亚胺培南的61株PA,MBL基因携带率则为87%。

    For sixty-one imipenem-resistant strains , the incidence of the MBL was 87 % .

  9. 耐亚胺培南鲍曼不动杆菌对3种舒巴坦复合剂耐药性的meta分析

    Comparison of Activities of Three Sulbactam Complex Against Imipenem Resistant Acinetobacter Baumannii Infections : A Meta Analysis

  10. 葡萄球菌对头孢唑啉、环丙沙星,肠球菌对青霉素G,大肠埃希菌和克雷伯菌属对头孢他啶、头抱吡肟以及铜绿假单胞菌对亚胺培南的敏感率均呈逐年下降趋势;

    The susceptive rates of staphylococci to cefazolin and ciprofloxacin , enterococci to penicillin G , escherichia coli ( E.coli ) and klebsiella sp . to ceftazidime and cefepime , P.

  11. 耐亚胺培南细菌金属β-内酰胺酶IMP基因的检测

    Detection of IMP Gene of Metallo - β - Lactamases In Imipenem-resistant Bacteria

  12. 目的调查某院重症监护室(ICU)分离的铜绿假单胞菌耐亚胺培南药物的现状及治疗结果。

    Objective To investigate the infection with imipenem-resistant Pseudomonas aeruginosa in a intensive care unit ( ICU ) and evaluate the treatment results .

  13. 方法用Etest试条法检测铜绿假单胞菌对亚胺培南的MIC值,用KB纸片法测定对其他11种抗菌药物的敏感性。

    Methods The MIC values of Pseudomonas aeruginosa to IMP were determined by E-test strips and their susceptibility to other 11 antimicrobial agents were tested by the Kirby-Bauer method .

  14. ESBLs阳性菌株与阴性菌株除亚胺培南耐药率为0外,其它抗菌药物之间的耐药率均存在高度显著性差异。

    Pneumoniae , the resistant rate of ESBLs positive and negative strains , except imipenem , had significant difference .

  15. 结论ICU为耐亚胺培南铜绿假单胞菌感染高发病区,也是多重耐药菌株感染较多的病区,应重点监控。

    Conclusion ICU is a high risk area of infection with imipenem-resistant Pseudomonas aeruginosa and other multiply-resistant bacteria , which should be given strengthened surveillance .

  16. 亚胺培南/西司他丁等对MRSA和MSSA的体外抗菌活性研究

    Study on the in vitro antibacterial activity of impenem / cilastatin against MRSA and MSSA

  17. 临床粘金黄杆菌676和592对亚胺培南敏感(MIC≤4ug/ml),我们使用它做诱导试验。

    The clinical isolates 676 and 592 which were sensitive to imipenem ( MIC ≤ 4ug / ml ) were chosen for drug resistance inducing test .

  18. 结论:21.7%的革兰阴性杆菌能产生IB。用亚胺培南作为诱导剂检测IB的生成,其作用优于头孢西丁。

    These results indicate that 21.7 % gram negative bacteria can produce inducible β lactamase and imipenem was more active than cefoxitin as inducer .

  19. 亚胺培南、头孢吡肟、头孢曲松和氨曲南对阴沟肠杆菌AmpC酶的诱导性研究南亚和东南亚区域局

    Comparative Induction of Imipenem , Cefepime , Ceftriaxone and Aztreonam to Enterobacter Cloacae AmpC β - lactamase ; Regional Bureau for South and South-East Asia

  20. 目的了解下呼吸道感染(LRTI)者痰检出耐亚胺培南铜绿假单孢菌(PA)的流行状况。

    Objective To study the prevalence of imipenem resistant pseudomonas aeruginosa ( IRPA ) from sputum in patients with lower respiratory tract infection ( LRTI ) .

  21. 所有对亚胺培南耐药鲍曼不动杆菌明确产OXA-23型碳青霉烯酶,未检出OXA-24、IMP、VIM基因型。

    All the 34 imipenem resistance isolates produced OXA-23 and no OXA-24 , IMP , VIM were detected .

  22. 结果显示,提高柱温或pH,选用硅胶柱或amideC16柱,均可改善亚胺培南峰形;

    It showed that the improvement of peak profile was favored by an increase of column temperature or pH , using silica gel column or Amide C 16 column .

  23. 方法利用K-B法、琼脂扩散法、微量稀释法测定临床铜绿假单胞菌与耐亚胺培南铜绿假单胞菌对抗菌药物的敏感性。

    METHODS K-B disc-diffusion , agar-diffusion and micro-dilution methods were applied to test the sensitivity to antibiotics of clinical isolated PAE and R-Imp PAE strains .

  24. 方法用PCR法对铜绿假单胞菌亚胺培南耐药相关的金属β-内酰胺酶IMP、VIM基因和外膜蛋白OprD2基因等3种主要耐药基因进行了检测与分析。

    METHODS PCR method was used to detect and analyze P.aeruginosa imipenem-resistance associated IMP gene and VIM gene of metallo - β - lactamases and outer membrane protein D2 ( OprD_2 ) gene .

  25. 结果48株亚胺培南耐药菌株均为多重耐药菌,对临床常用的多种抗菌药物耐药,敏感率由高到低依次为CIP、TOB、AMK、GEN和FEP;

    RESULTS All isolates were multiresistant , the orders of sensitivity rates of antibiotics were CIP , TOB , AMK , GEN , and FEP .

  26. 结论严重烧伤早期使用亚胺培南,痂下组织液和血浆中TNFα水平较对照明显降低,提示亚胺培南对TNFα、内毒素释放呈低诱导状态,有利于防止和减轻内毒素血症的发生。

    Conclusion Subeschar and plasma levels of TNF α can be significantly lowered with early-stage administration of imipenem , suggesting that IPM inhibits the release of TNF α and endotoxin to relieve or prevent endotoxemia after sever burn injury in rabbits .

  27. 结论耐亚胺培南铜绿假单胞菌临床分离株oprD基因变异具有多样性。

    Conclusions The mutations of Pseudomonas aeruginosa oprD gene in Imipenem-resistant clinical isolates are various .

  28. 亚胺培南在1×MIC及2×MIC浓度时诱导耐药突变频率分别为40×10-9及200×10-9,交叉耐药率20.8%。

    The resistance mutation frequency selected by 1 × MIC or 2 × MIC imipenem were 40 × 10 - 9 and 200 × 10 - 9 respectively , the cross resistance rate being 20.8 % .

  29. 结论通过RAPD分析了解耐亚胺培南铜绿假单胞菌基因型的特性,明确耐亚胺培南铜绿假单胞菌耐药的表型与基因型的关系,为该菌的感染控制提供分子流行病学依据。

    CONCLUSIONS RAPD assay reveals the special genotypes of imipenem-resistant P.aeruginosa and makes the relation between the phenotype of drug resistance with genotype of drug resistance definite , which provides molecular epidemiological evidence for strategies to control resistant imipenem P.aeruginosa infections .

  30. 结论美罗培南对革兰阴性杆菌有很强的抗菌活性,其抗菌活性要强于亚胺培南,是目前治疗肠杆菌科细菌特别是产ESBLs、AmpC酶细菌感染的危重患者的最理想用药。

    Conclusions Meropenem has better antibacterial activity against Gram-negative bacterial than imipenem . It is the reasonable drug to cure the serious patient with Gram-negative bacterial carrying ESBLs , AmpC enzyme and metallo-enzyme currently .